Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.

Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA.

Fam Cancer. 2013 Mar;12(1):101-9. doi: 10.1007/s10689-012-9585-8.

PMID:
23203849
2.

A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.

Michelsen TM, Dørum A, Dahl AA.

Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Epub 2009 Jan 29. Review.

PMID:
19178933
3.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
4.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851
5.

Prophylactic oophorectomy in women at increased cancer risk.

Domchek SM, Rebbeck TR.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. Review.

PMID:
17218848
6.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
7.

Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee.

Obstet Gynecol. 2010 Sep;116(3):733-43. doi: 10.1097/AOG.0b013e3181ec5fc1. Review.

PMID:
20733460
8.

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.

Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB.

BMC Womens Health. 2014 Dec 12;14:150. doi: 10.1186/s12905-014-0150-5. Review.

9.

[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].

Arai M, Iwase T, Takazawa Y, Takeshima N.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9. Review. Japanese.

PMID:
25434434
10.

Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.

Søgaard M, Kjaer SK, Gayther S.

Acta Obstet Gynecol Scand. 2006;85(1):93-105. Review.

PMID:
16521688
11.

[Management of hereditary ovarian cancer].

Joó JG, Ládi S, Nagy BZ, Langmár Z.

Orv Hetil. 2011 Oct 2;152(40):1596-608. doi: 10.1556/OH.2011.29218. Review. Hungarian.

PMID:
21945869
12.

Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.

Chene G, Rahimi K, Mes-Masson AM, Provencher D.

J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16. Review.

PMID:
23332575
13.

Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.

Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.

Gynecol Oncol. 2015 Dec;139(3):568-72. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25. Review.

PMID:
26407480
14.

New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.

Miller SM, Roussi P, Daly MB, Scarpato J.

Clin Cancer Res. 2010 Nov 1;16(21):5094-106. doi: 10.1158/1078-0432.CCR-09-2953. Epub 2010 Sep 9. Review.

15.

Clinical management of patients at inherited risk for gynecologic cancer.

Powell CB.

Curr Opin Obstet Gynecol. 2015 Feb;27(1):14-22. doi: 10.1097/GCO.0000000000000143. Review.

PMID:
25490378
16.

Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.

Long KC, Kauff ND.

Curr Opin Oncol. 2011 Sep;23(5):526-30. doi: 10.1097/CCO.0b013e3283499da9. Review.

PMID:
21734577
17.

Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J.

Arch Gynecol Obstet. 2015 Jul;292(1):231-4. doi: 10.1007/s00404-015-3697-y. Epub 2015 Apr 26. Review.

PMID:
25914073
18.

[Prophylactic salpingectomy or salpingo-oophorectomy as an ovarian cancer prevention?].

Chene G, Lamblin G, Le Bail-Carval K, Chabert P, Golfier F, Dauplat J, Deligdisch L, Penault-Llorca F, Mellier G.

Presse Med. 2015 Mar;44(3):317-23. doi: 10.1016/j.lpm.2014.07.024. Epub 2015 Jan 8. Review. French.

PMID:
25578546
19.

Challenging and complex decisions in the management of the BRCA mutation carrier.

Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.

J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29. Review.

20.

Role of salpingectomy at the time of urogynecologic surgery.

Bradley MS, Visco AG.

Curr Opin Obstet Gynecol. 2015 Oct;27(5):385-9. doi: 10.1097/GCO.0000000000000204. Review.

PMID:
26308195
Items per page

Supplemental Content

Write to the Help Desk